The 11th Annual Biologics Manufacturing Asia 2024 is Asia’s bioprocessing-focused, knowledge-sharing conference that provides regional biopharmaceutical industry stakeholders a carefully tailored networking platform for leveraging opportunities for strategic collaboration, and exposure to the latest manufacturing technologies and know-how. We have an agenda built around success stories from Asia’s biopharmas as well as the technical expertise from International Biopharmas and BIG Pharmas, presentations on the latest manufacturing technologies such as single-use and end-to-end continuous processing for biologics, today’s challenges and opportunities in biomanufacturing, advances in upstream process development, cost-optimization strategies in downstream processing, analytical characterization strategies, facility design, and scale-up strategy, fill & finish innovation to streamline the operations amongst other crucial themes.The BMA 2024 is co-located with 8th Annual Biologistics World Asia 2024, 2nd Clinical Trial Festival Asia 2024 and Asia-Pacific Bioprocessing Excellence Awards Gala Dinner 2024.
Yin Yin SIEW
Yudhi Li Xiu Long
A/Prof. Bi Xuezhi
Keqiang (Peter) Shen
Ciaran O’ Keeffe
Steve CL Lin
Andre Choo PhD
Kai Yin Po
Wei Kuang Chi
We have an agenda built around success stories from Asia’s biopharmas as well as technical expertise from international biopharmas and Big Pharmas, presentations on the latest manufacturing technologies such as single use and continuous processing for biologics, key challenges in cell therapy manufacturing, cost-reduction strategies in downstream processing, sustainability case studies surrounding single use systems, discussions on vaccine manufacturing, know-how on the developments in pathogen safety amongst other crucial themes.
The 10th Annual Biologics Manufacturing World Asia is the largest and the ONLY bioprocess business and technology convention in Asia Pacific! In 2023, 1000+ biomanufacturing stakeholders from Big Pharmas, Biopharmas, Contract Manufacturing Organisations, Academic & Research Institutes, Regulatory Authorities, Solution Providers across Singapore, China, South Korea, Taiwan, Japan, Australia, India, and SouthEast Asia, will convene hybridly to discover, discuss and debate about biologics manufacturing processes, best practices and latest developments to manufacture biologic drugs cheaper and faster!
Explore the most comprehensive upstream processing from early cell isolation and cultivation, cell line engineering, media development, raw materials considerations and more for enhancing and optimizing cell culture return and production rate with cost-reduction strategy. Know-how on the latest development of upstream processing technologies have evolved and potentially changed the biologics drug manufacturing process to be more economically feasible.
Immerse into the most focused biologics downstream processing with the ultimate goal of meeting quality and purity requirements of biologics drug products. Multiple purification approaches, concentration, product recovery, cost reduction and optimizing the integration of continuous manufacturing and utilization of single use disposable systems to optimize biologics manufacturing process production rate will be discussed.
Analytics & Quality
Innovative strategy of assay optimization, real time monitoring system with highest compromisation to quality control of biologics products to a direction of improving efficiency while advocating process automation are the keys to quicker market commercialization and regulatory compliance. Topics built around cost and process optimization with latest developments in analytics and quality to foster biologics enhancement.
Facility Design, Tech-Transfer & Scale-Up Strategy
Understand the challenges and the trends of biomanufacturing facility design in detail and find out the best practices of formulation and bulk technology transfer for optimizing output while maintaining quality and activity of products. Emphasis on scaling up processes without compromising product quality while discussing the latest technology and solution to scale up for maximum output.
Emerging Technologies and Applications
Identify the most imminent trends on the emerging technologies and applications with the potential to enhance and fasten the biologics manufacturing process. Applications such as PAT tools, novel technologies in single-use technologies and continuous processing, as well as automation and bioprocessing 4.0 to fasten the biologics manufacturing process will be discussed.
This year at the APAC regions biggest and only biologics focused conference, we are glad to introduce the first ever CMO Pavilion only at the 10th Annual Biologics Manufacturing Asia 2023, 15-16 March 2023 at Sands Expo & Convention Center, Marina Bay Sands, Singapore.
CMOs from over 10 countries in the APAC region will represent & showcase innovative development and manufacturing services and technologies to the largest gathering of 300+ biologics development companies only at the 10th Annual Biologics Manufacturing Asia 2023.
The Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA) seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality.
Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
- Best Bioprocessing Supplier Award: Upstream Processing
- Best Bioprocessing Supplier Award: Downstream Processing
- Best Bioprocessing Supplier Award: Fill-Finish
- Best Bioprocessing Supplier Award: Automation - Software
- Best Bioprocessing Supplier Award: Automation - Hardware
and many many more!
Safeguarding operator and patient safety as well as maintaining drug quality is crucial when manufacturing biologics.
This workshop condenses more than 15 years of expertise in single-use technology for frozen product handling and final filling, providing a perspective on the current state-of-the-art in single-use technologies, highlighting trends in technologies, while also addressing new challenges faced in the industry.
Pre-Register Here: https://imapac.com/sartorius_workshop/
Asia BioPharma (Biopharma in Asia, Academic & Research Institutes)
- BUY2GET3 & BUY3GET5
- 2- Day Conference Access
Early Bird: Biopharma Based outside of Asia
- 2- Day Conference Access
Early Bird: Solution Provider
- 2- Day Conference Access
ABEA 2023 Awards Pass: Gala Dinner
- Valid Until 30th Jan 2023
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
MasterControl Inc. is the leading provider of cloud-based quality and compliance software for life sciences and other regulated industries. Our mission is the same as that of our customers – to bring life-changing products to more people sooner.
You can use the MasterControl Product Lifecycle Excellence™ platform to digitize, automate and connect quality and compliance processes at every step – from concept to commercialization. Join over 1,000 companies worldwide that rely on MasterControl solutions to achieve new levels of operational excellence across product development, clinical trials, regulatory affairs, quality management, supply chain, manufacturing and postmarket surveillance.
Learn more at www.mastercontrol.com
Ajinomoto Genexine is providing customers with the CELLiST™ series developed based on Ajinomoto's media manufacturing technology and know-how,
which has been researching serum-free media for over 30 years, through a number of domestic and overseas agencies. https://en.ajinomotogenexine.
Since its inception, Hanbon Technology has been adhering to the original intention to provide biopharmaceutical users with drug purification equipment and services based on chromatography technology. The main products are: Biopharmaceutical downstream purification equipment, Industrial preparative liquid chromatography systems, Supercritical fluid chromatography systems, Continuous chromatography systems, Small nucleic acid synthesis and purification equipment, and can provide users with chromatography products as the core of the overall solutions and services. For more than 20 years, Hanbon has been following the wave of biopharmaceutical development, constantly developing new products and meeting the emerging needs of the market, providing R&D and production equipment for synthesis, purification and delivery of emerging small nucleic acid drugs, mRNA vaccines, cell therapy drugs, etc.
Website link: http://www.hanbon.com.cn/en/
AGC Biologics is a global CDMO with seven facilities worldwide providing process development and manufacturing services for protein-based biologics and advanced therapies. From development to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the development or manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, messenger RNA (mRNA), and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing (both clinical and commercial), Quality Control, and Quality Assurance and Process Validation.
“PharmNXTBiotech is a young Biotech Start-up based in Mumbai, it was established in the year 2017 with the idea of creating end-to-end bioprocess solutions and providing niche technologies to help reduce manufacturing costs for critical lifesaving drugs.
We recently inaugurated PharmNXTEkuse our brand new state-of-the-art single manufacturing facility based in Pune, which houses end-to-end solutions for the biopharma, vaccines manufacturing and containment solutions.
With the vision of “Make in India for the World,” we are ready to showcase our Xelta range of Single Use 2D, 3D bags and NXTmix Levitating mixing solutions along with our hardware technologies for downstream processing.
For containment solutions, we have our Make in India products: Flexible Isolators, Rigid Isolators as well as Powder Transfer Bags to handle potent molecules.”
Bio-Rad Laboratories is a leading provider to the life science and clinical diagnostics markets where the company’s products are used for scientific discovery, drug development, and biopharmaceutical production. Bio-Rad’s long-lasting customer relationships foster the company's research and development efforts and inspire the introduction of innovative products and solutions that accelerate the discovery process and improve healthcare. The Protein Purification Business, part of the Life Science Group at Bio-Rad, provides researchers with the chromatography tools they need to isolate and purify proteins from discovery through clinical trials into bioprocess manufacturing. With more than 60 years of purification experience, Bio-Rad continues to expand solutions to streamline the drug discovery and development process.
Bio-Rad Laboratories, Inc.
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development, and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.
For more information, please visit: avantorsc
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com
GenScript ProBio is the subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine, biologics discovery and antibody protein drug to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Founded in 2000, Truking Technology Limited has become one of the major pharmaceutical equipment suppliers in the world. The
company specializes in pharmaceutical equipment and the corresponding integrated solutions, and takes the initiative to push forward
the R&D of smart pharmaceutical factory.
It is a listed A-share company with multiple wholly-owned or controlling subsidiaries, namely Germany based Romaco Group, Truking
Watertown, Sichuan Pharmaceutical Degisn Institute, Truking Feiyun, Truking Ingenuity Biotechnology, Truking Wachine, Truking
Intelligent Robot, etc.
The company has over 6500 employees around the global, a total asset of RMB 6.9 billion and annual output value of RMB 8
billion.TRUKING has two operation headquarters respectively in Changsha, China and Germany; 4 big research institutes, namely
Changsha Central Technology Research Institute, Europe Technology Research Institute, Sichuan Pharmaceutical Design Institute, and
Suzhou Technology Research Institute.
Truking has established National Enterprise Technology Center, National Innovation Center, Post-Doctoral Research Center,
Academician Expert Workstation and many more technology and innovation platforms.
To better respond to the needs of global customers,Truking has been setting up sales and service centers in many countries including
India, Italy, Greece, Russia, Uzbekistan, Turkey, Egypt, Bangladesh, Korea, Vietnam, Thailand, etc.
By August 31, 2022, Truking has submitted 4342 patent applications, and been granted with 2684 patents.
Beyond China, Truking has applied for 40PCT international patents, and been granted with 20 patents in USA, Russia, India, Korea,
Germany, Indonesia, and many more European countries. Truking also took the lead in formulating 17 national industrial product
technical standards. Our products have been exported to more than 40 counties and regions to Asia, Europe, and South America.
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
Canton biologics is an international technology-based biopharmaceutical CRDMSO company with seven R&D and manufacturing centers around the world. With proprietary High-Titer cell lines(CHO K1/CHO-DG44/GLYCOEXPRESS, over 20g/L), complex protein high expression ability, and production capacity meeting international standards, we have been highly praised by customers.Our major technological breakthroughs have been made in IgMaxTM Expression Platform, IgMasterTM Process Platform, CHO-Rise® Proprietary expression medium, C-BoostTM Intensified Fed-batch Platform, Formulation technology (Lyophilization, Vaccine, nasal spray, lnhalation, Eye drops and High concentration formulation)and analysis. As a highly efficient company, we have created a new record that from DNA to CMC in only 7 months, which has played an important role in the rapid advancement of customers' products to clinical practice.In addition, we have 12+4 manufacturing lines complying with China, US and EU GMP standard(50-2000L ,batch, fed-batch, perfusion) for DS and DP manufacturing.
ValGenesis automates and develops intelligent engineering solutions for Life Sciences companies by optimizing the entire lifecycle of its products and processes to achieve operational excellence. Our state-of-the-art digital solutions fit into the culture, user-requirement specifications, regulatory demands, and the IT ecosystem of the pharmaceutical industry to assure our clients that our solutions are ready for validation, risk management, continuous process verification, and much more. We have innovative IT products and solutions that allow the Pharmaceutical Industry to update from Paper-based processes to leverage Pharma 4.0 and digitalization efforts.
Merck, a leading science and technology company, operates across life science, healthcare and
electronics. To the life science industry, we provide solutions and services for research,
biotechnology development and production, and pharmaceutical drug therapy development
The Millipore® portfolio of Merck offers an ecosystem of industry-leading products and
services, spanning preparation, separation, filtration, and monitoring, as well as clinical and
commercial biomanufacturing CTDMO services - all of which are deeply rooted in quality,
reliability and time-tested processes. The SAFC® portfolio of Merck offers customized and
ready-to-use raw material solutions, backed by deep regulatory expertise. Our proven products,
expert services and regulatory and application expertise are a strong foundation you can rely on
to consistently perform at the highest level.
For more information, please visit https://www.merckmillipore.com and
AcuraBio Pty Ltd is one of Australia’s most experienced microbial fermentation CDMOs (including microbial recombinant proteins), offering trusted, client-focused services to both domestic and international clients for the past 20 years.
World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research.
Leveraging decades of expertise in microbial expression systems, AcuraBio is now adding cGMP pDNA services to its service offering, offering plasmid DNA for therapeutic, vaccine and diagnostic applications including mRNA and viral vector based advanced therapies.
AcuraBio holds the following licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms (GMOs), and a DAF facility license for import and use of biologic materials.
Additional information about AcuraBio is available at www.acurabio.com.
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF has been present in Singapore since 1978, supplying customers from various industries, including chemicals, construction, electronics, personal care, and health and nutrition. The company today operates four production facilities in Singapore, as well as Human Nutrition Application Lab Asia Pacific for its nutrition and health business. BASF posted sales to customers in Singapore of about €312 million in 2021 and had 505 employees as of the end of the year.
At Astrea Bioseparations every detail matters as we work to create tailored solutions that streamline bioprocesses from research through commercial phases. We actively support customers with products and services that enable them to bring next-generation therapies to the market to treat and cure diseases
IKA is a leading manufacturer of laboratory equipment, analytical and process technology. Headquartered in Germany, we opened our first subsidiary in the U.S. in 1985. After a decade of steady growth in the world markets, the first Asian subsidiary was founded in Malaysia in 1995 to serve the booming Asian market. From then onwards, the IKA Group kept growing and continues to grow to this day. In 1998, the Chinese subsidiary in Guangzhou was added, which has since expanded to include sales offices in Beijing and Shanghai. IKA Works Japan and IKA India, as well as branches in Brazil, South Korea, Vietnam, Great Britain, Poland, Thailand and Turkey followed some time later. Today, a total of 15 branches in 13 countries ensure excellent service worldwide.
Our website: www.ika.com
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
Evonik is one of the world leaders in the specialty chemicals industry. Active in more than 100 countries around the world, Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. We contribute small amounts of material that make a big difference. We provide the highest quality cell culture media ingredients for biologic drugs development & manufacturing, produce lipid nanoparticles essential in mRNA-based COVID-19 vaccines, make tires more fuel-efficient, and animal feeds healthier. As one of the key growth regions, Evonik has a strong production and R&D footprint in Asia Pacific. With over 5,000 employees at more than 50 production sites, the region contributed to €3.4 billion sales in 2021.
At Evonik, we offer high-quality cell culture solutions to pharmaceutical and biotech companies to help them boost cell culture performance in the manufacturing of therapeutic proteins like monoclonal antibodies, as well as in the production of viral vectors such as the adeno associated viral (AAV) vectors for gene therapy.
Commercially proven for reliable media performance across countless biological programs, our cQrex® portfolio features a range of peptides and keto acids designed to address key issues in mammalian cell culture.
Our latest offering, plant-derived cholesterol PhytoChol® Biopharma, which has been especially developed for use in animal-free cell culture media formulation, for example in chemically defined media which do not use fetal bovine serum (FBS). In addition, specialty carbohydrates like D-Mannose can be used as alternative energy sources and building blocks for intracellular protein glycosylation, enabling a higher flexibility in the production of therapeutic proteins.
All these cell culture ingredients are non-animal derived, readily available at commercial scale and can be customized to address specific project needs.
Learn more about Evonik’s cell culture expertise at https://healthcare.evonik.com/en/biopharma/cell-culture.
Bausch+Ströbel is a trusted and experienced supplier to the pharmaceutical industry specializing in filling and packaging systems. B+S filling and packaging lines are used worldwide to fill syringes, vials, cartridges and ampoules with high-grade liquid and powder pharmaceutical products. Applications range from cleaning and sterilization to labelling and syringe assembly. In addition to designing and building systems tailored to customer specifications, Bausch+Ströbel provide a wide range of specialized services aimed at ensuring system reliability and productivity.
JSBio is committed to becoming a world-class leader in cell culture technology and a supplier of high-quality culture medium products. It is one of the few teams in China that has a complete CMC production and operation system. Since its establishment, JSBio has always adhered to the concept of "Quality First, Customer Focused" by providing high-quality products for partners in the antibody/recombinant protein and human/veterinary vaccine industries. From basic research to commercial stages of therapeutics and vaccines, JSBio's products and services meet the highest quality and regulatory standards of the industry.
The leadership team of the JSBio are world-class culture medium manufacturers and biopharmaceutical executives. Since the establishment of the company, JSBio has served 200+ antibody/recombinant protein, human/veterinary vaccine customers, including 100+ Phase Ⅰ/II clinical projects, 30+ phase III clinical projects, and 20+ commercialization phase projects.
After ten years of development, JSBio's business has expanded to nearly 30 provinces, municipalities and autonomous regions in China, and has also extended to overseas markets such as Asia-Pacific, Europe and the United States. JSBio provides customers with high-quality culture medium products and related cell culture process services that meet multinational standards, and has also enabled the development of the biopharmaceutical industry.
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services, for primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO).
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral
drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for
all parenteral applications. We provide sterile injectable contract development and manufacturing (CDMO) services from initial combination device design and formulation development to commercial manufacturing.
supporting better patient outcomes around the world.
We listen. We question. We deliver.
- The 3M biopharmaceutical business is a subset of the 3M Separation and Purification Sciences Division which utilizes cutting edge 3M material science that pushes the boundaries of purification, filtration, and separation to support production, processes that change lives, and deliver quality solutions where it matters most.
- Our biopharma and materials science expertise can help you improve in-process purity, increase the yield of your product and lower manufacturing costs – so you can focus on bringing life-saving treatments to trial and market
- Biopharmaceutical Purification | 3M
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry. https://www.lonza.com/
EuBiologics is developing new vaccine products with the goal of distributing safe and effective vaccines that can contribute to the promotion of global public health. In addition, it is a specialized bio company that provides CRMO (Contract Research and Manufacturing Organization) services for various biopharmaceuticals based on advanced facilities suitable for biopharmaceutical research and production, professional manpower, and rich experience in the field. Starting with Euvichol-Plus, which occupies more than 80% of the global cholera vaccine market, EuBiologics is developing new infectious disease preventive vaccines using EuIMT using the immune enhancer EcML and EuVCT technology using the recombinant protein rCRM197.
We have a cGMP-level plant (C Plant & V Plant), and we provide customized CRMO services in consideration of improving product quality and securing competitiveness for the entire production cycle of biopharmaceuticals derived from mammalian cells and microorganisms, from cell line development to GMP production.
Since 1998, Ami Polymer is in the business of Silicone Elastomeric products and also, other Polymeric components which ultimately provide solutions to Fluid Transfers, Sealing, and Contamination controls for Biopharma, Pharma, Medical, Laboratory, Food, Beverages, and Engineering sectors worldwide. We Are Experts in Silicone Tubing, Hoses & Single-Use Assemblies.
Ami Polymer is having ISO Class VII and ISO Class VIII Cleanroom facilities certified with ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 27001:2013, ISO 13485:2016. We also have a BPOG extractables program for our products for regulatory markets worldwide.
ABER is the market leader in bio-capacitance sensors with unparalleled experience and expertise in the field, boasting a world class team to guide users in finding effective solutions to their process monitoring needs.
ArcticZymes Technologies ASA is born from the unique conditions in the Arctic and our innovations in Tromsø (Norway) where we have been developing and manufacturing cold-adapted enzymes for more than 30 years. We are a specialized manufacturer of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD), and biomanufacturing.
In biotherapeutics such as oncolytic virus therapy, gene therapy and vaccine production our enzymes are tailor-made for optimal performance in multiple bioprocessing and biomanufacturing workflows. Beyond the unique features, ArcticZymes Technologies is committed to providing premium and highest quality enzymes, with emphasis on robust manufacturing and reliability of supply. Our no-compromises approach to become a long-term partner with our customers has enabled countless innovations and products to successfully reach the market. Furthermore, our enzymes targeted for biotherapeutic use are specially developed to suit high quality measurements and regulatory requirements simplifying their use in GMP compliant processes.
Aptamer Group develops custom affinity binders for use across the life sciences using its proprietary Optimer® platform. Optimer binders can be used as antibody alternatives to offer novel or improved solutions in downstream affinity purification and QC assays to support product release. Optimer binders are removing the barriers to innovation in the life sciences by offering simple resin compatibility, tuneable binding kinetics and high stability. https://aptamergroup.com/
Mitsui Chemicals is one of Japanese leading chemical companies, providing many world-class products to over 160 companies in 30 countries. Among them, InnoCell™ is one of the latest innovations for the biopharmaceutical industry. By making the base of the cell culture vessel from our material, it is possible to efficiently supply cells with approximately 200 times more oxygen than when using a conventional culture plate.
Tofflon Science and Technology Group Co. Ltd. was established in 1993 and is a one-stop solution provider for bio/pharmaceutical industry. Besides being a comprehensive pharmaceutical equipment supplier, Tofflon also provides process support, core equipment, integrated systems, pharma engineering (Modular construction & Site build construction) and consumables such as media, resin and single use systems for the pharma and biotech industry around the world.
Since founded, Tofflon has supplied and supported more than 12,000 sets of equipment and systems for 3,000 pharmaceutical companies across over 50 countries and regions in the world which have been widely applied in the fields of R&D, liquid and lyo injectables, chemical API, bioengineering and pharma packaging. Tofflon has also been approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, ASME, PED, etc.Today, Tofflon Science and Technology Group Co. Ltd has over 5500 employees around the globe with a total asset of over 2 billion USD. The company currently has several R&D centres around the world (China, Italy and Germany) and is expanding further. Through our Technological Innovation and Development Concept: Automation, Intelligence, Modularization, Continuous Processing and System Integration, we create values for the industry and our partners: cGMP compliance, High Efficiency, Automation, Simple Interface, Cost Effective, Easy Validation, Integrated Service, and Faster Time to Market.
Eppendorf – Stimulating growth. Cultivating Solutions Efficient bioprocesses are central to the production of biopharmaceuticals, biomass, chemical building blocks, and nutritional products. Scientists from industry and academia trust Eppendorf bioprocess solutions for the cultivation of mammalian, insect, plant, and stem cells, as well as bacteria, yeasts, and fungi. Scalable systems support the upstream bioprocessing cycle from early development to scale-up to pilot-scale production, in working volumes from 65 mL to 2,400 L. Powerful hardware and software tools for process monitoring, control, and analytics, help to build process understanding and facilitate standardized process control. By utilizing the strong synergies between bioreactor technology and polymer manufacturing, Eppendorf developed a wide selection of single-use bioreactors and fermentors which complement its portfolio of glass and stainless-steel vessels. With worldwide technical and application services, clear technical documentation, and preventive maintenance services, Eppendorf ensures reliable system operation. Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 5000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.
Quality Executive Partners (QxP) is a global premier consulting and training firm to the pharma, biotech, and life sciences industries. QxP's team of deeply skilled experts provide innovative and pragmatic solutions which address development, commercialization and business needs simultaneously. Our success is defined by the transfer of knowledge to our clients, enabling them to develop and commercialize quality products sustainably. QxP is the creator of the Virtuosi platform for pharmaceutical workforce education, covering aseptic processing, quality control microbiology, and cell and gene therapy manufacturing. Based on a “learn and do” methodology, Virtuosi features more than 50 on-demand e-learning video courses, and 25 virtual reality activities. Virtuosi is available in five languages.
“An organization taking pride in providing engineering and construction project management consultancy (PMC) for greenfield and brownfield industrial high-tech projects. Leveraging on established network among investment agencies, industrial parks and local authorities, Medhini is well positioned to support projects from early inception such as site selection, project charter initiation and concept development. Working with various partners, we are able to initiate an early start and avoid regulatory hiccups. Added value includes Industry 4.0 implementation support, lean construction strategies, training programs with local and international universities for capacity building, media engagement in science communications among others.
We have also partnered and represent DD Enterprise for the ASEAN region. DDE is a leading enterprise engaged in designing, manufacturing, qualification and commissioning of sterile process systems. By envisioning smarter ideas, greener technologies and solutions, DDE have been redefining boundaries in the high purity business while working with bio-pharma, vaccine and sterile formulations industries for the last 25 years. DDE products offer consistent quality, reliability and repeatability as they use customized designs, state of the art design tools, best manufacturing practices, highest quality components integrated with fully automated and intelligent control systems and full cGMP documentation package.”
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
For more information about Pfanstiehl Inc, and their products and solutions, please contact us at [email protected] or visit www.Pfanstiehl.com
Emerson is where technology and engineering come together to create solutions for the benefit of our customers, driven without compromise for a world in action. As a global innovator, Emerson has a deep legacy of solving the most complex challenges facing modern life. We combine advanced technologies, industry-leading expertise and an insatiable curiosity about the world around us to create sustainable solutions for the essential customers we serve.
Our how is complex, but our why is simple and found in our unified global Purpose: We drive innovation that makes the world healthier, safer, smarter and more sustainable. https://www.emerson.com/en-sg/
Samsung Biologics is a fully integrated CDMO partner providing tailored solutions to clients. Our end-to-end services include upstream and downstream process development, clinical and commercial manufacturing, aseptic fill/finish, and bioanalytical testing—all at one site. Our plants are cGMP-compliant holding 604KL total capacity (upon completion of Plant 4 in 1H 2023) with a range of bioreactor scales. We also provide mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish including dedicated QC & MSAT laboratory, labeling & packaging, as well as cold chain storage.
With more than 130 years of experience, Dr. Paul Lohmann® is a German expert in salt manufacturing and provides DPL-BioPharm Salts for the biopharmaceutical industry. These salts act as nutrients for cell cultures, as buffering and post-harvest processing agents within upstream processing. For downstream processing various acetates, citrates, phosphates and sulfates enable efficient bioprocesses for separation, precipitation and purification.
Visit us at https://www.lohmann4minerals.
Or contact us at [email protected] Paul Lohmann®
Our vision is to empower decision-making in the processing industries with innovative simulation tools and tailored services to contribute to a sustainable future worth living in. We believe that simulation offers unparalleled levels of insight into complex processes and their prospective behavior. Leveraging this potential means making more confident decisions in process development and plant operations. It means that we can learn from tomorrow, today. To achieve these ambitious goals, we have organized the INOSIM Group as a Software and a Consulting branch.
For nearly twenty years now, INOSIM Software has been a synonym for high-end performance in the simulation solutions market. During that period, we have set technological standards in many process industries: According to our customers, there is no other simulation tool offering the flexibility and comprehensiveness provided by our scalable standard software and its extensions for optimization and statistical analysis. INOSIM software has provided solutions for a variety of companies in the processing industries. Historically, our core customers have been chemical companies, but in the recent years, many pharmaceutical and biotechnical companies have recognized the potential of our sophisticated simulation tools. Additionally, several engineering service providers use our tools in their projects. Using our software tools, engineers can handle a wide range of simulation projects. Mainly our products are used to simulate process logistics and execute material flow analysis. In such projects, the entire plant is modeled or extended to simulate plant operations and to analyze the plant’s performance with varying influences such as limited equipment, resources (employees, utilities, logistics, etc.), failures, and/or maintenance. Next to software development and sales, research is an important factor in our strategy to ensure that our software products remain state-of-the-art. Therefore, we are consistently involved in collaborative research projects to create solutions for industrial challenges influenced by the latest in academic research.
INOSIM Consulting is a world-wide engineering service provider with branches in Germany, India, and the U.S. Core activities include the simulation based analysis of complex logistics and production systems in chemical, biochemical and pharmaceutical industries.Additionally, INOSIM Consulting is strongly involved in collaborative research projects about resource and energy efficiency in production processes. INOSIM Consulting is closely connected to INOSIM Software and is responsible for first-level support and training on INOSIM software solutions.
If you would like to know more, please visit our website at www.inosim.com or give us a call at +91 9766 331 092.
Founded in 2001, Mycenax Biotech Inc. (MBI) is a CDMO company offering integrated services for the development and manufacturing of biologic products, including cell line generation, process, formulation, and analytical method developments, GMP production for both mammalian and microbial systems, and fill-finish for both liquid and lyophilized forms.
MBI has extensive experience in developing biologic products for our clients around the globe. Ranging from small peptides, fusion proteins, and monoclonal antibodies, to cell therapy products, we provide our clients with time- and cost-effective services through our high-standard technology platforms and PIC/S GMP certified manufacturing facility. For the cell line development, we recently introduced the Beacon® Optofluidic System (Berkeley Lights, US) to streamline the workflow and provide strong evidence for monoclonality. For process development, we are pioneered in developing continuous bioprocess. For GMP manufacturing, our 2 nd GMP facility, which hosts 2 production lines with up to six 2,000L bioreactors will be completed in mid-2021 to further expand our GMP production capacity.
With our innovative technology and qualified GMP facilities, we are the best partner for clients worldwide for developing biologic products at all developmental stages.
For more information, please visit our booth or website at: http://www.mycenax.com.tw/en
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organization, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry.
For ongoing news, visit www.a-star.edu.sg.
Cold Chain Platform (CCP) is 100% focused on cold chain and logistics in the biopharmaceutical, life science, and healthcare industries. CCP services help global companies reach the right partners and get a firm foothold in the Asia Pacific. CCP works with global organizations to help them gain access to the APAC cold chain, logistics, and pharmaceutical market through a highly targeted audience.
BioPharma Asia aims to keep its readers abreast of all developments in the areas of Manufacturing, Development, Quality Assurance, Outsourcing, and Regulatory Affairs, with only the highest quality articles and webinars written and presented by the most respected authors/presenters, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.
Present your expertise to the Asian Bioprocessing industry’s key stakeholders through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.